Tech Company Financing Transactions
Akouos Funding Round
On 12/1/2017, Akouos landed $7.5 million in Seed funding from 5AM Ventures, New Enterprise Associates and Partners Innovation Fund.
Transaction Overview
Company Name
Announced On
12/1/2017
Transaction Type
Venture Equity
Amount
$7,500,000
Round
Seed
Investors
5AM Ventures (Lead Investor) (Kush Parmar)
New Enterprise Associates (Lead Investor) (Edward Mathers)
Proceeds Purpose
Concurrent with the financing, Akouos entered into strategic license agreements with Lonza and Massachusetts Eye and Ear for exclusive rights to the Anc-AAV gene therapy platform for all hearing and balance disorders.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
645 Summer St. 200
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Akouos (Nasdaq: AKUS) is developing targeted therapies to restore and preserve hearing in genetically-defined patient populations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emmanuel Simons
Chief Medical Officer
Michael McKenna
Chief Scientific Officer
Gregory Robinson
VP - Bus. Development
Morgan Molloy
VP - Bus. Development
Rabia Ozden
VP - Finance
Aninda Katragadda
VP - General Counsel
Karoline Shair
VP - Human Resources
Steve Burke
VP - Product Management
John Connelly
VP - Regulatory Affairs
Jennifer Wellman
Browse more venture capital transactions:
Prev: 12/1/2017: TetraVue venture capital transaction
Next: 12/4/2017: Companion Medical venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs